Efficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment of Refractory Epilepsy. Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society

French, Jacqueline A.; Kanner, Andrés M.; Bautista, Jocelyn F.; Abou‐Khalil, Bassel; Browne, Thomas R.; Harden, Cynthia L.; Theodore, William H.; Bazil, Carl W.; Stern, John M.; Schachter, Steven C.; Bergen, Donna; Hirtz, Deborah; Montouris, Georgia; Nespeca, Mark; Gidal, Barry E.; Marks, William J.; Turk, William R.; Fischer, James H.; Bourgeois, Blaise; Wilner, Andrew N.; Faught, R. Edward; Sachdeo, Rǎjesh C.; Beydoun, Ahmad; Glauser, Tracy A.

doi:10.1111/j.0013-9580.2004.20041020.x

Cited by 37 publications

(51 citation statements)

References 45 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4.1 Efficacy of OXC: seizure reduction and persistence of the efficacy Although there are many similarities between OXC and CBZ, OXC, a kind of new AED, seems to have better tolerance, safety, and efficacy. OXC is recommended by the International League Against Epilepsy (ILAE) and the American Academy of Neurology (AAN), mainly to be used as monotherapy and add-on therapy for partial epilepsy of adults and children [6][7][8][9]. OXC showed good efficacy in monotherapy for partial epilepsy, especially in treating the patients with short course of disease who had never had AEDs [10].…”

Section: Discussionmentioning

confidence: 99%

Prospective research on the efficacy and safety of oxcarbazepine as monotherapy and add-on therapy for partial epilepsy

Liu

et al. 2009

Front. Med. China

View full text Add to dashboard Cite

The purpose of our research was to evaluate the efficacy, tolerance, and safety of oxcarbazepine (OXC) as monotherapy and add-on therapy for partial epilepsy. We carried out a prospective clinical follow-up trial at the Epilepsy Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Sixty-seven patients with partial epilepsy received OXC therapy. The patients were randomly divided into a monotherapy group and an add-on therapy group. We observed the efficacy and safety in the first three months and the following three months respectively, and compared them with each other. There was a significant difference in the decrease of seizure frequency between the two groups (P = 0.002). There was a significant difference in the percentage of seizure-free between the monotherapy and the add-on therapy groups in the first three months (P = 0.02), and there were also statistical differences in the 50% response rate (P = 0.017) and the percentage of seizure-free in the following three months (P = 0.019). No difference was found in the 50% response rate, the 75% response rate, and the percentage of seizure-free between the first three months and the following three months in the whole group and the two subgroups (P > 0.05). The incidence rate of side effects due to the therapy was 19.40% (13 of 67). The side effects were mainly found in the first three months. It is concluded that OXC is the first-line anti-epileptic drug (AED) for partial seizures, and could be used as the monotherapy and add-on therapy for newly diagnosed patients and patients that failed to tolerate or benefit from other AEDs.

show abstract

Section: Discussionmentioning

confidence: 99%

Prospective research on the efficacy and safety of oxcarbazepine as monotherapy and add-on therapy for partial epilepsy

Liu

et al. 2009

Front. Med. China

View full text Add to dashboard Cite

show abstract

“…This greater portion of the (R)-enantiomer after OXC metabolization might hypothetically be responsible for diverse AEs and a higher interaction potential when compared with ESL, which does not have unnecessary production of enantiomers or diastereoisomers of metabolites and their conjugates [15][16][17][18][19][20][21][22].…”

Section: Drug Profilementioning

confidence: 99%

“…Besides overall similar affinity of ESL and CBZ for the VGSC, the affinity of ESL for the resting state of the channel has been shown to be approximately threefold lower, possibly being reflected in higher inhibitory selectivity for rapidly firing neurons [15][16][17][18][19][20][21][22][23][24][25].…”

Section: Mechanism Of Actionmentioning

confidence: 99%

Eslicarbazepine acetate for partial-onset seizures

Rauchenzauner

Luef

2011

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Eslicarbazepine acetate (ESL), a new voltage-gated sodium channel blocker that is chemically related to carbamazepine and partially metabolized to oxcarbazepine, has attracted attention as results of previous Phase II and III studies demonstrated and confirmed efficacy and tolerability of ESL 800 and 1200 mg once daily as add-on therapy for adult patients with drug-resistant partial-onset seizures. In children, efficacy data point towards a dose-dependent decrease in seizure frequency and tolerability analyses showed a low incidence of mild drug-related adverse effects at 5 and 15 mg/kg/day. The most frequently reported adverse effects were dizziness, somnolence, headache, diplopia, nausea and vomiting. The convenience of once-daily dosing and a short/simple titration regimen in combination with a comparative efficacy and tolerability profile might promote ESL as a valid alternative to the current adjunctive antiepileptic drug therapy armamentarium for drug-resistant partial seizures in adults. Since clinical trials in children and adolescents on ESL efficacy and safety are ongoing and data already published are far from conclusive, the therapeutic value of ESL in this special population has to be established in the near future.

show abstract

“…In 2004 on behalf of a joint committee of the AAN and the American Epilepsy Society, French et al 5,6 issued a report regarding the efficacy and tolerability of new antiepileptics in the treatment of refractory epilepsy. In this report, 345 articles were analyzed, 90 on GBP, 60 on LTG, 63 on TPM, 6 on TGB, 44 on OXC, 33 on ZNS, and 11 on LEV.…”

Section: Refractory Epilepsymentioning

confidence: 99%

“…3,[5][6][7] These reports follow a systematic process in which a clinically relevant issue and multidisciplinary task force are chosen, as well as a clinically relevant question including the patient population (for example: adults, children, newly diagnosed epilepsy), type of study (prognostic factor, treatment, new antiepileptic drugs), and the course of the clinical parameter evaluated (efficacy, tolerability). In the bibliographic search, the articles are classified by 2 independent reviewers into level I (prospective, randomized, controlled clinical trials), corresponding to the most complete evidence for treatment recommendations and which are used, when available, to support the conclusions of the clinical guideline, and levels II through IV, which include other clinical trials, cohort studies, case series, or isolated case reports, providing weaker recommendations to be used when no level I studies are available.…”

mentioning

confidence: 99%

Antiepileptic Drugs

García‐Morales¹,

Rieger²,

Gil‐Nagel³

et al. 2007

The Neurologist

View full text Add to dashboard Cite

We have found that in all types of epilepsy [except in focal epilepsy in children where a new drug (oxcarbamazepine) is considered to be the first choice for initial treatment], classic drugs (valproic acid in idiopathic generalized epilepsy and carbamazepine in focal epilepsy) are recommended as long as there are no contraindications due to adverse effects or concomitant use of other drugs that interact with the antiepileptics. However, despite the general recommendations, it can be deduced from the studies and reflections on the subject that the decision as to whether to start treatment or not, as well as the drug of choice, must be made on a case-by-case basis, taking into account the patient's personal and social circumstances.

show abstract

Efficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment of Refractory Epilepsy. Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society

Cited by 37 publications

References 45 publications

Prospective research on the efficacy and safety of oxcarbazepine as monotherapy and add-on therapy for partial epilepsy

Prospective research on the efficacy and safety of oxcarbazepine as monotherapy and add-on therapy for partial epilepsy

Eslicarbazepine acetate for partial-onset seizures

Antiepileptic Drugs

Contact Info

Product

Resources

About